Biomerieux, Inc.

Université Des Sciences Et Technologies De Lille

Centre National De La Recherche Scientifique

Institut Curie

Biomerieux Sa

Université Des Sciences Et Technologies De Lille Saic

Chu De Dijon

Geneviève Choquet-Kastylevsky

Jean-Philippe Charrier

Sandrine Busseret

Corinne Beaulieu

Dominique Rolland

Monique Arpin

Arnaud Salvador

Hubert Hondermarck

Sylvie Pons

Florence Poirier

Yasemin Ataman-Önal

Jérôme Lemoine

Yohann Demont

Jean Faivre

Hader Haidous

Odile Mejan-letourneur

Sandrine Michel-busseret

Gaspard Gervasi

Emanuelle Gallet-Gorius

Michèle Guillotte

Céline Hamelin

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer

A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.

Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Growing community of inventors

Francheville, France

Geneviève Choquet-Kastylevsky